What question did this study set out to answer?

This research aims to assess the efficacy and safety of a new gene-modifying CAR platform in reducing tumors and depleting B-cells.

Anti-Tumor Activity of Novel Gene-Modifying CAR Lentivector in Humanized Models

View Full Paper

Ask AI

Bookmark

This research aims to assess the efficacy and safety of a new gene-modifying CAR platform in reducing tumors and depleting B-cells.
Developed a GCAR platform incorporating a CD3-targeted lentivector with costimulatory proteins.
Evaluated GCAR LVVs in vitro and in vivo using humanized and non-human primate models.
Characterized CD3 reactivity and assessed B-cell depletion using flow cytometry and various assays.
GCAR LVVs effectively cleared tumors in PBMC-humanized models.
Demonstrated durable B-cell depletion lasting over eight weeks in humanized models.
Administration showed no severe toxicity in non-human primates and indicated dose-dependent B-cell depletion kinetics.

No takes yet. Share an insight, caveat, or question.

In vivo evaluation demonstrates anti-tumor effects and B-cell aplasia in primate models, suggesting clinical potential.

Betts et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark